Journals / Online Türk Sağlık Bilimleri Dergisi / 2023 / Cilt: 8 - Sayı: 1

Fibrosis-4 Index as a Predictor for Disease Severity and Mortality in Patients with COVID-19

COVID-19 Hastalarında Hastalık Şiddeti ve Mortalite için Bir Öngörücü Olarak Fibrozis-4 Indeksi

Pages
134–139
Publication Date
2023-03-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The FIB-4 index is an independent predictor of severity and mortality in COVID-19 patients requiring ICU.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The Fibrosis-4 (FIB-4) index is a noninvasive marker of liver fibrosis in various patient populations.
📊
Key Findings & Data:We examined whether there is a relationship between the severity and prognosis of COVID-19 disease and the FIB-4 index.
💡
Conclusion & Impact:Conclusion: The FIB-4 index is an independent predictor of severity and mortality in COVID-19 patients requiring ICU.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:COVİD-19 · FİB-4 İNDEX · mortalite

Abstract

Objective: The Fibrosis-4 (FIB-4) index is a noninvasive marker of liver fibrosis in various patient populations. We examined whether there is a relationship between the severity and prognosis of COVID-19 disease and the FIB-4 index. Materials and Methods: This stuy is a cross-sectional and retrospective. The patients were divided into two groups as those hospitalized in the intensive care unit (ICU) and those hospitalized in the clinic (non- ICU). Results: Of the total 158 cases,86(54%) were male. Age, total bilirubin, AST levels and FIB-4 index were higher in ICU patients compared to non-ICUs (p<0.001,p=0.002, p=0.003, p<0.001 respectively). FIB-4 index non-survivors were also higher (p=0.002). When the effect of the FIB-4 index on the severity of COVID-19 disease and mortality was evaluated by ROC analysis, both ICU and non-survivors were found to be significant (respectively FIB-4 score;AUC=0.705,95%CI:0.624-785,p<0.001;AUC=0.654,95%CI:0.566-742,p=0.002). When the FIB-4 index cut-off value for disease severity was taken as 2.19, 70.0% sensitivity and 60% specificity were found in predicting disease severity. Moreover, when the FIB-4 index cut-off value for mortality was taken as 2.19, 71.2% sensitivity and 53% specificity were found in predicting mortality. Conclusion: The FIB-4 index is an independent predictor of severity and mortality in COVID-19 patients requiring ICU.

Özet

Amaç: Fibrosis 4 (FIB-4) index çeşitli hasta popülasyonlarında karaciğer fibrozisini gösteren non invaziv bir belirteçdir. Çalışmamızda COVİD-19 hastalığının ciddiyeti ve mortalite ile FIB-4 skoru arasında ilişki olup olmadığını incelemeyi planladık. Gereç ve Yöntem: Bu çalışma kesitsel retrospektiftir. COVID-19 tanısı doğrulanmış olup hastanede yatan 158 hastayı içermektedir. Hastalar yoğun bakım ünitesinde (ICU) yatanlar ve kliniğe yatırılanlar (non-ICU) olarak iki gruba ayrıldı. Bulgular: Toplam 158 olgunun 86 (50%)’sı erkek idi. Yaş, total bilirubin, AST ve FIB-4 index yoğun bakım ünitesinde yatanlarda yoğun bakımda yatmayanlarla karşılaştırıldığında sırasıyla (p<0,001, p=0,002, p=0,003, p<0,001 ) idi. FIB-4 index hayatta kalmayanlarda daha yüsekti (p=0,002). FIB-4 skorunun COVİD-19 ciddiyetini ve mortaliteyi öngörmedeki etkisi ROC analizi ile değerlendirildiğinde hem yoğun bakımda yatan hemde hayatta kalmayanlarda anlamlı bulundu (sırasıyla AUC=0,705, 95%CI: 0.624-785, p<0,001; AUC=0,654, 95%CI:0,566-742, p=0,002). Hastalık şiddeti için FIB-4 indeks için cut-off değeri 2,19 olarak alındığında hastalık şiddetini öngörmede %70,0 duyarlılık ve %60 özgüllük bulunmuştur. Ayrıca, mortalite için FIB-4 indeksi için cut-off değeri 2,19 olarak alındığında, mortaliteyi öngörmede %71,2 duyarlılık ve %53 özgüllük bulunmuştur. Sonuç: FIB-4 indeksi yoğun bakım gerektiren COVİD-19 hastalarının cidiyetini ve mortaliteyi belirlemede bağımsız bir öngördürücüdür.

🔖

Cite This Article

NALBANT, A., KAYA, T., YAYLACI, S., AYDIN, A., İŞSEVER, K., GENÇ, A. C. (2023). Fibrosis-4 Index as a Predictor for Disease Severity and Mortality in Patients with COVID-19. Online Türk Sağlık Bilimleri Dergisi, Cilt: 8 - Sayı: 1, 134–139. https://ajindex.com/articles/888096

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel corona virus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. doi:10.1016/S0140-6736(20)30211-7
  2. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with corona virüs disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180(7):934-943. doi: 10.1001/jamainternmed.2020.0994
  3. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;20;382(8):727-733. doi.org/10.1056/NEJMoa2001017
  4. Hundt MA, Deng Y, Ciarleglio MM, Nathanson M, Lim JK. Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. Hepatology. 2020; 72(4):1169-1176. doi.org/1 0.1002/hep.31487
  5. Bloom PP, Meyerowitz EA, Reinus Z, et al. Liver biochemistries in hospitalized patients with COVID-19. Hepatology. 2020; 73(3):890-900. doi. org/10.1002/hep.31326
  6. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of corona virus disease 2019 in China. N Engl J Med. 2020; 382:1708–1720. doi. org/10.1056/NEJMoa2002032
  7. Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020; 158:1999–2014. doi:10.1053/j.gastro.2019.11.312 8. Gines P, Graupera I, Lammert F, et al. Screening for liver fibrosis in the general population: a callforaction. Lancet Gastroenterol Hepatol. 2016; 1:256–60. doi:10.1016/s2468-1253(16)30081-4
  8. Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020; 158:1611–1625. doi: 10.1053/j.gastro.2020.01.043
  9. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43(6):1317-1325. doi.org/10.1002/hep.21178
  10. Kim BK, Kim DY, Park JY, et al Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010; 30(4):546-53. doi: 10.1111/j.1478-3231.2009.02192.x
  11. Ibáñez-Samaniego L, Bighelli F, Usón C, et al. Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in